| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The unlabeled parent compound, 17beta-Estradiol-3-beta-D-glucuronide, is an estrogen metabolite known to inhibit multidrug resistance proteins (MRP) such as MRP2 and MRP3. It is a well-known causative agent of intrahepatic cholestasis (reduced bile flow) in humans. This metabolite is also a substrate for organic anion-transporting polypeptides (OATPs).
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as tracers for quantification throughout the drug development process. Due to its potential to alter the pharmacokinetic and metabolic characteristics of medications, deuteration has drawn attention[1].
As an internal standard, the labeled compound has no biological activity. The unlabeled parent compound has been shown in vitro to inhibit MRP2 and MRP3-mediated transport. It is a cholestatic agent that causes a decrease in bile salt export pump (BSEP) activity, contributing to the accumulation of bile acids in hepatocytes. |
| Enzyme Assay |
A standard LC-MS/MS protocol is used. A known amount of the d3-labeled internal standard is spiked into biological samples (e.g., plasma, bile, liver homogenate). After protein precipitation and solid-phase extraction, the sample is injected onto a C18 column. The analyte and internal standard are detected in MRM mode, and the peak area ratio is used for precise quantification.
|
| Cell Assay |
The labeled compound is used as an internal standard for measuring the concentration of the unlabeled metabolite in cell culture media. For example, primary human hepatocytes are treated with estradiol, and the media is collected. The d3-internal standard is spiked into the media to quantify the amount of glucuronidated metabolite produced, which reflects the metabolic activity of the UGT enzymes.
|
| Animal Protocol |
The internal standard is spiked into blood, bile, or urine samples collected from animal models. It is used to accurately measure the concentration of the endogenous metabolite or a dosed compound. This is particularly important in models of drug-induced liver injury (DILI) or intrahepatic cholestasis to monitor the role of estrogen metabolites in bile flow reduction.
|
| ADME/Pharmacokinetics |
The labeled compound has a molecular weight of 473.51 and is stable when stored at 4degC in a sealed container, away from moisture and light. It is soluble in water and organic solvents. As an analytical standard, it co-elutes with the non-labeled analyte in LC and is distinguishable by MS. Stability data is provided for solvents at -80degC for 6 months.
|
| Toxicity/Toxicokinetics |
The deuterated compound is non-toxic at the trace concentrations used for analytical purposes. The unlabeled parent compound is an endogenous estrogen metabolite that can cause intrahepatic cholestasis at supraphysiological concentrations. The product is "For research use only" and not for human therapeutic or diagnostic use.
|
| References | |
| Additional Infomation |
17beta-Estradiol-3-beta-D-glucuronide-d3 sodium is a research-grade stable isotope-labeled chemical (Internal Standard) used for LC-MS/MS quantitation. It is not a drug and has no FDA approval for therapeutic use. It is used in pharmaceutical research for studying estrogen metabolism, drug-induced liver injury (DILI), and intrahepatic cholestasis (ICP). It is an essential tool for method validation in bioanalysis.
|
| Molecular Formula |
C24H28D3NAO8
|
|---|---|
| Molecular Weight |
473.51
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1119 mL | 10.5594 mL | 21.1189 mL | |
| 5 mM | 0.4224 mL | 2.1119 mL | 4.2238 mL | |
| 10 mM | 0.2112 mL | 1.0559 mL | 2.1119 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
